605 569

Cited 42 times in

A hypoxia- and {alpha}-fetoprotein-dependent oncolytic adenovirus exhibits specific killing of hepatocellular carcinomas

DC Field Value Language
dc.contributor.author권오준-
dc.contributor.author김평환-
dc.contributor.author윤채옥-
dc.date.accessioned2015-04-23T17:36:18Z-
dc.date.available2015-04-23T17:36:18Z-
dc.date.issued2010-
dc.identifier.issn1078-0432-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/102781-
dc.description.abstractPURPOSE: Oncolytic adenoviruses (Ad) constitute a new promising modality of cancer gene therapy that displays improved efficacy over nonreplicating Ads. We have previously shown that an E1B 19-kDa-deleted oncolytic Ad exhibits a strong cell-killing effect but lacks tumor selectivity. To achieve hepatoma-restricted cytotoxicity and enhance replication of Ad within the context of tumor microenvironment, we used a modified human α-fetoprotein (hAFP) promoter to control the replication of Ad with a hypoxia response element (HRE). EXPERIMENTAL DESIGN: We constructed Ad-HRE(6)/hAFPΔ19 and Ad-HRE(12)/hAFPΔ19 that incorporated either 6 or 12 copies of HRE upstream of promoter. The promoter activity and specificity to hepatoma were examined by luciferase assay and fluorescence-activated cell sorting analysis. In addition, the AFP expression- and hypoxia-dependent in vitro cytotoxicity of Ad-HRE(6)/hAFPΔ19 and Ad-HRE(12)/hAFPΔ19 was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay and cytopathic effect assay. In vivo tumoricidal activity on subcutaneous and liver orthotopic model was monitored by noninvasive molecular imaging. RESULTS: Ad-HRE(12)/hAFPΔ19 exhibited enhanced tumor selectivity and cell-killing activity when compared with Ad-hAFPΔ19. The tumoricidal activity of Ad-HRE(12)/hAFPΔ19 resulted in significant inhibition of tumor growth in both subcutaneous and orthotopic models. Histologic examination of the primary tumor after treatment confirmed accumulation of viral particles near hypoxic areas. Furthermore, Ad-HRE(12)/hAFPΔ19 did not cause severe inflammatory immune response and toxicity after systemic injection. CONCLUSIONS: The results presented here show the advantages of incorporating HREs into a hAFP promoter-driven oncolytic virus. This system is unique in that it acts in both a tissue-specific and tumor environment-selective manner. The greatly enhanced selectivity and tumoricidal activity of Ad-HRE(12)/hAFPΔ19 make it a promising therapeutic agent in the treatment of liver cancers-
dc.description.statementOfResponsibilityopen-
dc.format.extent6071~6082-
dc.relation.isPartOfCLINICAL CANCER RESEARCH-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdenoviridae/genetics*-
dc.subject.MESHAdenoviridae/physiology-
dc.subject.MESHAnimals-
dc.subject.MESHApoptosis*/physiology-
dc.subject.MESHCarcinoma, Hepatocellular/genetics-
dc.subject.MESHCarcinoma, Hepatocellular/pathology-
dc.subject.MESHCarcinoma, Hepatocellular/therapy*-
dc.subject.MESHCell Hypoxia/physiology-
dc.subject.MESHCell Line, Tumor-
dc.subject.MESHHumans-
dc.subject.MESHLiver Neoplasms/genetics-
dc.subject.MESHLiver Neoplasms/pathology-
dc.subject.MESHLiver Neoplasms/therapy*-
dc.subject.MESHMale-
dc.subject.MESHMice-
dc.subject.MESHMice, Nude-
dc.subject.MESHOncolytic Virotherapy/methods*-
dc.subject.MESHPromoter Regions, Genetic-
dc.subject.MESHSubstrate Specificity/genetics-
dc.subject.MESHXenograft Model Antitumor Assays-
dc.subject.MESHalpha-Fetoproteins/genetics*-
dc.titleA hypoxia- and {alpha}-fetoprotein-dependent oncolytic adenovirus exhibits specific killing of hepatocellular carcinomas-
dc.typeArticle-
dc.contributor.collegeResearcher Institutes (부설 연구소)-
dc.contributor.departmentInstitute for Cancer Research (암연구소)-
dc.contributor.googleauthorOh-Joon Kwon-
dc.contributor.googleauthorPyung-Hwan Kim-
dc.contributor.googleauthorSteven Huyn-
dc.contributor.googleauthorLily Wu-
dc.contributor.googleauthorMinjung Kim-
dc.contributor.googleauthorChae-Ok Yun-
dc.identifier.doi10.1158/1078-0432.CCR-10-0664-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA00236-
dc.contributor.localIdA01088-
dc.contributor.localIdA02614-
dc.relation.journalcodeJ00564-
dc.identifier.pmid21169258-
dc.contributor.alternativeNameKwon, Oh Joon-
dc.contributor.alternativeNameKim, Pyung Hwan-
dc.contributor.alternativeNameYun, Chae Ok-
dc.contributor.affiliatedAuthorKwon, Oh Joon-
dc.contributor.affiliatedAuthorKim, Pyung Hwan-
dc.contributor.affiliatedAuthorYun, Chae Ok-
dc.citation.volume16-
dc.citation.number24-
dc.citation.startPage6071-
dc.citation.endPage6082-
dc.identifier.bibliographicCitationCLINICAL CANCER RESEARCH, Vol.16(24) : 6071-6082, 2010-
Appears in Collections:
1. College of Medicine (의과대학) > Research Institute (부설연구소) > 1. Journal Papers
1. College of Medicine (의과대학) > Yonsei Biomedical Research Center (연세의생명연구원) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.